

Mitigation Response to Influenza A (H1N1) Virus Infection



National Center for Disease Prevention and Control, DOH



Objectives

- To slow down the virus spread in the community & minimize transmission to the most vulnerable group
- To improve health facility preparedness in providing necessary treatment particularly for severe cases to reduce mortality impact
- To minimize social disruption & other negative consequences



National Center for Disease Prevention and Control, DOH



Severity Assessment

- Virological factor (Properties of the virus)
 - Self-limiting infections in majority of infected individuals
 - Can cause very severe form of infections among the high risk group
- Population vulnerability
 - Relatively high in the Philippines
- Capacity to respond
 - Established outbreak response mechanism at national & regional levels



Components/Framework of Response

- Command system
- Surveillance
- Health facility response
- Public health interventions
- Risk communication



Stepwise Approach

- Mitigation response level 1
 - A few sporadic cases
 - No clustering of cases
 - No community level transmission
- Mitigation response level 2
 - Beginning of community level transmission
 - Clustering of confirmed cases of Influenza A (H1N1) in defined communities or specific areas (schools, workplace, etc...)
- Mitigation response level 3
 - Sustained community transmission
 - A series of clusters in a population in a given period of time & becoming wider in a given geographical area



Response Matrix

Command System

- DOH Task Force (National / CHDs)
- NDCC / RDCC (DOH Secretary is the de facto chair currently)
- Local Task Force on Influenza A (H1N1)
 - Provincial, municipal, city

Command system should be functional at all mitigation response levels



Mitigation Response Level 1

Surveillance	Health Facility Response
<ul style="list-style-type: none"> • Laboratory Surveillance <ul style="list-style-type: none"> • If it fits the case definition of Case Under Observation, needs to perform confirmatory exam • Disease Surveillance <ul style="list-style-type: none"> • Look for clustering of cases • If with clustering of ILI, needs to perform random confirmatory exam • Contact tracing • Event based surveillance 	<ul style="list-style-type: none"> • Identify referral hospitals <ul style="list-style-type: none"> • check number of beds, isolation rooms, respirators, etc... • Capacitate referral hospitals to manage confirmed cases • Intensify infection control • Prepare essential meds & equipments incl. protocols • Admit ALL confirmed cases • Antiviral meds to all probable & confirmed cases • Prepare RHU / Health Centers / Private clinics & Primary hospitals to manage mild cases, ambulatory cases or screen ILI & establish referral system for severe cases



Mitigation Response Level 1

Public Health Interventions	Risk Communication
<ul style="list-style-type: none"> • Containment measures • Non-pharmaceutical interventions <ul style="list-style-type: none"> • Quarantine • Isolation • Social distancing • School closure • intensify infection control program in the community • infection control committee, trainings, available PPEs, protocols 	<ul style="list-style-type: none"> • Focus on individual, household & public awareness • Prevention • Infection control <ul style="list-style-type: none"> • Hand hygiene • Cough manners • Containment • Provide accurate & up to date information • Prepare, reproduce & distribute information materials specific for containment & mitigation measures



Mitigation Response Level 2

Surveillance	Health Facility Response
<ul style="list-style-type: none"> • Laboratory Surveillance <ul style="list-style-type: none"> • If it fits the case definition of CUO, needs to perform confirmatory exam • Scale up lab capacity to cope up with the increasing number of CUO • When community transmission has been established in an area, conduct random sampling of CUOs to establish if there is sustained transmission • Disease Surveillance <ul style="list-style-type: none"> • Establish the extent of spread of the disease & if there is sustained community level transmission • Event based surveillance • If community transmission has been established, no need to perform contact tracing 	<ul style="list-style-type: none"> • If community transmission has been observed in the affected area: <ul style="list-style-type: none"> • Mild cases to be observed / managed at home • Admit probable & confirmed cases showing signs of respiratory infections & severe medical conditions • Treatment dose of Oseltamivir for the compromised / vulnerable sick group • No prophylaxis dose for close contacts except for health care providers exposed to probable & confirmed case without use of appropriate PPE • Triage at the hospitals, public health centers & clinics • Hospitals, health centers & clinics should be ready to handle surge of consultations & possible admissions or referrals • Intensify infection control in hospitals, health centers & clinics



Mitigation Response Level 2

Public Health Interventions	Risk Communication
<ul style="list-style-type: none"> • Non-pharmaceutical interventions <ul style="list-style-type: none"> • Home confinement / Isolation of mild cases • Isolation for cases admitted in hospitals • Social distancing for close contacts • Social distancing like school closure will depend on local epidemiological situation • intensify infection control program in the community • infection control committee, trainings, available PPEs, protocols 	<ul style="list-style-type: none"> • Focus on individual, household & public awareness • Prevention • Infection control same as level 1 • Containment • Mitigation measures • Provide accurate & up to date information • Special attention to the vulnerable group of population most likely to develop complications • Emphasize self quarantine for the exposed & home treatment for the mild cases, early consultation to prevent complications & severe outcome of the disease • Continuous information to the public through IEC • Communication should focus on the DOH best efforts to contain the disease, until such time that mitigation process has to start • Mitigation process has to be proactive



Mitigation Response Level 3

Surveillance	Health Facility Response
<ul style="list-style-type: none"> • Laboratory Surveillance <ul style="list-style-type: none"> • RITM & other laboratory to prioritize high risk groups • Lab exam to include monitoring the properties of the virus (mutation, resistance, etc...) • Disease Surveillance <ul style="list-style-type: none"> • No more contact tracing • Monitoring disease to know if activity levels are going up or down • Monitor changes in the natural history of the disease 	<ul style="list-style-type: none"> • Admit severe respiratory infections & with severe medical conditions • Public & private hospitals should be prepared to manage higher number of complicated, severe cases • Health centers, RHUs / private clinics should be prepared to manage higher number of mild cases as out patient or ambulatory cases • Prioritize treatment dose of oseltamivir • Public health facilities (RHUs, health centers) to be ready to admit severe / complicated cases once the surge capacity of the hospitals can no longer address the need of the pandemic



Mitigation Response Level 3

Public Health Interventions	Risk Communication
<ul style="list-style-type: none"> • Non-pharmaceutical interventions same as above • Use of appropriate PPEs, facility modified to cater the infection control measure needs, systems flow • Debriefing of frontline health workers 	<ul style="list-style-type: none"> • Sustain level of public awareness • Mitigation measures • Infection control • Provide accurate & up to date information • Minimize fear, anxiety & unrest • Continuous information to the public through IEC

- Referral system must be functional in all mitigation response levels



Major Policy Changes from Containment to Mitigation Response to the Influenza A (H1N1) Outbreak in the Country



National Center for Disease Prevention and Control, DOH



Major Policy Changes

	FROM	TO
Infection Control Measures	Provisions of Interim Guidelines Nos. 1 to 15 (issued between May 4 to June 8, 2009)	In response to observation of index cases & cohort of cases & WHO Pandemic Phase 6
1. Prophylaxis with the anti-viral (oseltamivir)	<ul style="list-style-type: none"> • For ALL first responders or health care workers tending suspected, probable & confirmed cases • For ALL household & close contacts (Interim Guidelines nos. 1, 2 & 8) 	<p>SELECTIVE Prophylaxis</p> <ul style="list-style-type: none"> • Post exposure prophylaxis ONLY for close contacts with existing unstable medical conditions that may be aggravated by a viral infection • NO pre-exposure prophylaxis for health care workers or first responders • Post exposure prophylaxis for health care workers who did not have adequate PPE when in contact with confirmed cases



National Center for Disease Prevention and Control, DOH



Major Policy Changes

	FROM	TO
2. Anti-viral treatment for confirmed Influenza A (H1N1) cases	<ul style="list-style-type: none"> • For ALL confirmed (positive) cases of Influenza A (H1N1) (Interim Guidelines nos. 1 & 2) 	<p>Limited to specific indications & with medical supervision</p> <ul style="list-style-type: none"> • Anti-viral treatment ONLY for confirmed cases with: <ul style="list-style-type: none"> • Severe or progressive illness • Pre-existing or concurrent medical condition that compromise system or pulmonary function • Emphasize: Use anti-viral in pregnancy ONLY when benefits outweigh the risk to embryo or fetus



Major Policy Changes

	FROM	TO
3. Quarantine Rule for Travellers	<ul style="list-style-type: none"> • Home quarantine for 10 days for ALL travellers coming from countries reporting confirmed cases of Influenza A (H1N1), with or without ILI 	<p>RESPONSIBLE SELF MONITORING</p> <ul style="list-style-type: none"> • Travellers shall monitor self for 10 days after arrival, observe for signs & symptoms of ILI & submit to National DOH Guidelines if ILI develops • For patients diagnosed as confirmed case of Influenza A (H1N1) & intending to travel outside the Philippines, travel clearance shall be provided 7 days after resolution of fever



Major Policy Changes

	FROM	TO
4. Confinement or isolation & quarantine measures for suspected cases or CUOs	<ul style="list-style-type: none"> • For ALL suspected cases or CUO (ILI & history of recent travel or exposure to confirmed cases) until laboratory results are obtained (Interim Guidelines no. 15) 	<p>RESPONSIBLE, VOLUNTARY CONFINEMENT</p> <ul style="list-style-type: none"> • In general, voluntary home confinement • Hospital admission only when clinically indicated



Major Policy Changes

	FROM	TO
5. Confinement or Isolation of Probable or Confirmed Cases	<ul style="list-style-type: none"> • “Probable & confirmed cases shall remain in confinement... until asymptomatic” (Interim Guidelines no. 2) 	<p>MEDICALLY PRESCRIBED Hospital Confinement</p> <ul style="list-style-type: none"> • A great majority of probable & confirmed cases are for home care. They are those with stable clinical manifestations or those identified when they were in the recovery stage of the illness • Hospital admission criteria include those manifesting with respiratory difficulty, progressively acute illness & debility & others belonging to risk groups



Major Policy Changes

	FROM	TO
6. Laboratory Diagnosis	<ul style="list-style-type: none"> • For suspected cases & CUOs • At the Research Institute for Tropical Medicine (Interim Guidelines nos. 3, 7 & 15) 	<p>SELECTIVE Laboratory Confirmatory Testing</p> <ul style="list-style-type: none"> • Indications for laboratory testing are: <ul style="list-style-type: none"> • Mandatory investigation of CUOs identified at various ports of entry in the country • Investigation of first suspect cases in a specific area or community • Random sampling of persons in clusters with ILI manifesting with unusual symptoms or severity • Investigation of ILI in persons at high risk of developing complications because of other medical conditions or problems • NO LABORATORY FOLLOW-UP TESTS ARE NECESSARY PRIOR TO DISCHARGE



Major Policy Changes

	FROM	TO
7. Reporting of Influenza A (H1N1) Suspects or CUOs	<ul style="list-style-type: none"> • Mandatory reporting of ILI among travellers from countries where there are confirmed cases & of close contacts of confirmed cases • Reporting of all rumors on occurrence of ILIs (Interim Guidelines no. 7) 	<ul style="list-style-type: none"> • Routine reporting of ILI through the nationwide Philippine Integrated Disease & Surveillance Reporting System (PIDSRS) • Pursue screening & reporting of persons with ILI detected at international ports of entry



Major Policy Changes

	FROM	TO
8. Contact Tracing	<ul style="list-style-type: none">• For ALL close contacts of confirmed cases (Interim Guidelines no. 14)	<ul style="list-style-type: none">• Routine contact tracing for disease investigation shall only be conducted to document first & second generation transmission in communities or specific areas with no previous cases based on the assessment of CHDs & local health officials



Individuals at Increased Risk for Hospitalizations and Death

- Elderly ≥ 60 years
- Children less than two years
- Certain chronic diseases
 - Heart or lung disease, including asthma, pneumonia who needs hospitalization in 2nd or 3rd level of care
 - Metabolic disease, including uncontrolled diabetes
 - HIV/AIDs, other immunosuppression, organ transplant patient
 - Conditions that can compromise respiratory function or the handling of respiratory secretions like COPD, PTB (active & untreated), MDRTB or previous pulmonary pathology which requires hospitalization
 - Patient with rapid progression of disease
 - Patient with criterion for admission in ICU
 - Patient with severe malnutrition



Individuals at Increased Risk for Hospitalizations and Death

- Certain chronic diseases
 - Complex congenital cardiopathy that requires hospitalization in 2nd or 3rd level of care
 - Chronic renal insufficiency that requires hospitalizations
 - Heart defect or previous cardiac pathology that requires hospitalization
 - Patients with underlying chronic diseases that present progression to deterioration
- Pregnant women



Thank You!

